Table 1.

A summary of trials included in the Cochrane review [1].

Characteristic			Trials
			MXFa vs AM-CLb, Vick-Fragoso et al [3]	AB103 vs placebo, Bulger et al [4]	IVIGc vs placebo, Madsen et al [5]
Groups			1. MXF 400 mg once daily 2. AM-CL 3 g three times daily for at least 3 days followed by 1.5 g three times daily	1. AB103 0.5 mg/kg 2. AB103 0.25 mg/kg 3. Placebo Single intravenous dose within 6 hours after diagnosis	1. IVIG 25 g/day for 3 consecutive days 2. Placebo
Participants, n			54 (MXF group: n=36; AM-CL group: n=18)	43 (AB103 group: n=32; placebo group: n=11)	100 (IVIG group: n=50; placebo group: n=50)
Overall risk of bias			High (attrition, imbalance, performance, detection)	Moderate (attrition)	High (attrition, imbalance)
Primary outcomes
	Mortality within 30 days		No difference (RRd 3.00, 95% CI 0.39-23.0)	No difference (RR 0.34, 95% CI 0.05-2.16)	No difference (RR 1.17, 95% CI 0.42-3.23)
		Certainty of evidence	Very low	Very low	Low
	Proportion of patients who experienced serious adverse events		Not specified; no difference (RR 0.63, 95% CI 0.30-1.31)	Not specified; no difference (RR 1.49, 95% CI 0.52-4.27)	Acute kidney injury, allergic reactions, aseptic meningitis, hemolytic anemia, thrombi, and infections; no difference (RR 0.73, CI 95% 0.32-1.65)
		Certainty of evidence	Very low	Very low	Low
Secondary outcomes
	Survival time (median time of death)		Shorter in the MXF group (10.5 days vs 42 days); no statistical analysis was possible	Not specified	Shorter in the IVIG group (25 days vs 49 days); no statistical analysis was possible
	Assessment of long‐term morbidity		Not specified	Not specified	No difference in the median physical component summary scores between groups (mean adjusted difference 1, 95% CI 7-10; P=.81)

^aMXF: moxifloxacin.

^bAM-CL: amoxicillin‐clavulanate.

^cIVIG intravenous immunoglobulin.

^dRR risk ratio.